Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Hutchmed China Ltd ADR (HCM)

Hutchmed China Ltd ADR (HCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
HUTCHMED Granted Breakthrough Therapy Designation for Combination of ORPATHYS® and TAGRISSO® in Treating Advanced Non-Small Cell Lung Cancer Quiver Quantitative, Inc. - Thu Dec 12, 8:20AM CST

HUTCHMED announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® combination for advanced lung cancer.Quiver AI SummaryHUTCHMED has received Breakthrough Therapy Designation from...

HCM : 14.31 (-2.05%)
HUTCHMED and Innovent Announce First Regulatory Approval of Fruquintinib Combination Therapy with Sintilimab for Advanced Endometrial Cancer in China Quiver Quantitative, Inc. - Tue Dec 3, 2:24PM CST

HUTCHMED and Innovent announced conditional approval for fruquintinib plus sintilimab combination therapy for advanced endometrial cancer in China.Quiver AI SummaryHUTCHMED and Innovent Biologics have...

HCM : 14.31 (-2.05%)
HUTCHMED Announces Renewal of Inclusion for ORPATHYS® in China's National Reimbursement Drug List Effective January 1, 2025 Quiver Quantitative, Inc. - Thu Nov 28, 2:56PM CST

HUTCHMED announces ORPATHYS® will remain on China's National Reimbursement Drug List following contract renewal with NHSA.Quiver AI SummaryHUTCHMED (China) Limited announced that ORPATHYS® (savolitinib)...

HCM : 14.31 (-2.05%)
HUTCHMED Receives Milestone Payment as FRUZAQLA® Launches in Japan for Metastatic Colorectal Cancer Quiver Quantitative, Inc. - Fri Nov 22, 8:48AM CST

HUTCHMED announces FRUZAQLA® launch in Japan for metastatic colorectal cancer after regulatory approval and milestone payment from Takeda.Quiver AI SummaryHUTCHMED has announced the approval and launch...

HCM : 14.31 (-2.05%)
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket FinancialNewsMedia - Fri Oct 4, 8:15AM CDT

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
BGNE : 176.50 (+1.02%)
HCM : 14.31 (-2.05%)
ABBV : 175.58 (+2.37%)
ONC.TO : 1.19 (-9.16%)
ELVN : 22.47 (-1.75%)
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket Newswire.ca - Fri Oct 4, 8:00AM CDT

/CNW/ -- USA News Group News Commentary – While some forms of cancer are seeing death rates fall, the world is witnessing a global surge in cancers among...

ONCY : 0.8310 (-6.36%)
BGNE : 176.50 (+1.02%)
HCM : 14.31 (-2.05%)
ABBV : 175.58 (+2.37%)
ONC.TO : 1.19 (-9.16%)
ELVN : 22.47 (-1.75%)
Inmagene and HUTCHMED Announce First Participant in Global Phase I Trial of IMG-004 Globe Newswire - Tue Aug 9, 2022

SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited...

HCM : 14.31 (-2.05%)
HCM.LN : 237.000 (-0.42%)
HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial Globe Newswire - Mon Aug 8, 2022

— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy — — Global SAFFRON Phase...

HCM : 14.31 (-2.05%)
HCM.LN : 237.000 (-0.42%)
HUTCHMED Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer Globe Newswire - Sun Aug 7, 2022

— Trial met primary endpoint of overall survival and all secondary endpoints — — Overall safety consistent with fruquintinib known profile — — Plans for...

HCM : 14.31 (-2.05%)
HCM.LN : 237.000 (-0.42%)
HUTCHMED Reports 2022 Interim Results and Provides Business Updates Globe Newswire - Mon Aug 1, 2022

Oncology/Immunology revenues up 113% to $91.1 million, due to ELUNATE®, SULANDA® and ORPATHYS® growth First presentation of SAVANNAH data...

HCM : 14.31 (-2.05%)
HCM.LN : 237.000 (-0.42%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot